Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure

Circulation Research

Volumn 85, Issue 5, 1999, Pages 437-445

  Ekelund, Ulf E G ^a   Harrison, Robert W ^a   Shokek, Ori ^a   Thakkar, Rajiv N ^a   Tunin, Richard S ^a   Senzaki, Hideaki ^a   Kass, David A ^a   Marbán, Eduardo ^a   Hare, Joshua M ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Heart failure; Myocardial contractility; Oxidant stress; Xanthine oxidase

Indexed keywords

ALLOPURINOL; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; ENERGY EXPENDITURE; ENZYME ACTIVITY; HEART FAILURE; HEART MUSCLE; HEART MUSCLE OXYGEN CONSUMPTION; HEART PACING; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYOFILAMENT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0033520357     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.5.437     Document Type: Article

References (51)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429-1435.
2. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468-1475.
3. Suga H. Ventricular energetics. Physiol Rev. 1990;70:247-277.
4. Ishihara H, Yokota M, Sobue T, Saito H. Relation between ventriculoarterial coupling and myocardial energetics in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;23:406-416.
5. Ingwall JS. Is cardiac failure a consequence of decreased energy reserve? Circulation. 1993;87(suppl VII):VII-58-VII-62.
6. Haikala H, Linden I. Mechanism of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol. 1995;26:S10-S19.
7. Pérez NG, Hashimoto K, McCune S, Altschuld RA, Marbán E. Origin of contractile dysfunction in heart failure: calcium cycling versus myofilaments. Circulation. 1999;99:1077-1083.
8. De Tombe PP. Altered contractile function in heart failure. Cardiovasc Res. 1998;37:360-366.
9. Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem. 1995;270: 18797-18803.
10. + channels. Circ Res. 1995;76:325-334.
11. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science. 1998;279:234-237,
12. Cardillo C, Kilcoyne M, Cannon RO III, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30:57-63.
13. Ghatak A, Brar MJ, Agarwal A, Goel N, Rastogi AK, Vaish AK, Sircar AR, Chandra M. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol. 1996;57:119-127.
14. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159-163.
15. Rouquette M, Page S, Bryant R, Benboubetra M, Stevens CR, Blake DR, Whish WD, Harrison R, Tosh D. Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett. 1998;426:397-401.
16. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A. 1996;93:8745-8749.
17. Tan S, Gelman S, Wheat JK, Parks DA. Circulating xanthine oxidase in human ischemia reperfusion. South Med J. 1995;88:479-482.
18. Nielsen VG, Tan S, Baird MS, Samuelson PN, McCammon AT, Parks DA. Xanthine oxidase mediates myocardial injury after hepatoenteric ischemia-reperfusion. Crit Care Med. 1997;25:1044-1050.
19. de Jong JW. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res. 1990;67:770-773.
20. Abadeh S, Case PC, Harrison R. Purification of xanthine oxidase from human heart. Biochem Soc Trans. 1993;21(suppl):99S.
21. Abadeh S, Case PC, Harrison R. Demonstration of xanthine oxidase in human heart. Biochem Soc Trans. 1992;20(suppl):346S.
22. Bakhtiyarov ZA. Changes in xanthine oxidase activity in patients with circulatory failure. Ter Arkh. 1989;61:68-69.
23. Pérez NG, Gao WD, Marbán E. Novel myofilament calcium-sensitizing property of xanthine oxidase inhibitors. Circ Res. 1998;83:423-430.
24. Insel PA. Analgesic-antipyretic and antiinflammatory agents. In: Gilman AG, Hardman JG, Limbird LE, eds. The Pharmalogical Basis of Therapeutics. 9th ed. New York, NY: McGraw Hill; 1998;649-650.
25. Jones RM. Clinical comparison of inhalation anaesthetic agents. Br J Anaesth. 1984;56(suppl 1):57S-69S.
26. Eger EI. The pharmacology of isoflurane. Br J Anaesth. 1984;56(suppl 1):71S-99S.
27. 2 wasting effect. Anesthesiology. 1997;87:82-93.
28. Baan J, van der Velde ET, van Dijk AD, Kerkhof PLM, Buis B, Koops J. Ventricular volume measured from intracardiac dimensions with impedance catheter: theoretical and experimental aspects. In: Cardiovascular System Dynamics: Models and Measurements. New York, NY: Plenum Press; 1992:569.
29. Kass DA, Yamazaki T, Burkhoff D, Maughan WL, Sagawa K. Determination of left ventricular end-systolic pressure-volume relationships by the conductance (volume) catheter technique. Circulation. 1986;73: 586-595.
30. Little WC, Freeman GL, O'Rourke AR. Simultaneous determination of left ventricular end-systolic pressure-volume and pressure-dimension relationships in closed-chest dogs. Circulation. 1985;71:1301-1308.
31. Kass DA. Myocardial mechanics. In: Poole-Wilson P, Colucci W, Massie B, Chatterjee K, Coats A, eds. Heart Failure. New York, NY: Churchill Livingstone; 1997:87-108.
32. Kelly RP, Ting C-T, Yang T-M, Liu C-P, Maughan WL, Chang M-S, Kass DA. Effective arterial elastance as index of arterial vascular load in humans. Circulation. 1992;86:513-521.
33. Little WC, Cheng CP, Mumma M, Igarashi Y, Vinten-Johansen J, Johnston WE. Comparison of measures of left ventricular contractile performance derived from pressure-volume loops in conscious dogs. Circulation. 1989;80:1378-1387.
34. Rahko PS. Comparative efficacy of three indexes of left ventricular performance derived from pressure-volume loops in heart failure induced by tachypacing. J Am Coll Cardiol. 1994;23:209-218.
35. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res. 1989;64:827-852.
36. Suga H, Hisano R, Goto Y, Yamada O, Igarash, Y. Effect of positive inotropic agents on the relation between oxygen consumption and systolic pressure volume area in canine left ventricle. Circ Res. 1983;53:306-318.
37. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet. 1998; 352(suppl I):I-34-I-38.
38. Belch JJF, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J. 1991;65:245-248.
39. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol. 1997;80(11A):41L-45L.
40. Gao WD, Liu Y, Marbán E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle: implications for the mechanism of stunned myocardium. Circulation. 1994;94:2597-2604.
41. Fan D, Wannenburg T, De Tombe PP. Decreased myocyte tension development and calcium responsiveness in rat right ventricular pressure overload. Circulation. 1997;95:2312-2317.
42. Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM, Dietzschold B, Maeda H. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci U S A. 1996;93:2448-2453.
43. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 1997;275:1649-1652.
44. Stryer L. Biochemistry. 4th ed. New York, NY: WH Freeman and Company; 1998:756.
45. Massey V, Komai H, Palmer G, Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo [3,4-d]pyrimidines. J Biol Chem. 1970;245:2837-2844.
46. Kelly RA, Smith TW. Drugs used in the treatment of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia, Pa: WB Saunders Co Inc; 1997: 471-491.
47. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997;280:247-254.
48. Miyamoto Y, Akaike T, Yoshida M, Goto S, Horie H, Maeda H. Potentiation of nitric oxide-mediated vasorelaxation by xanthine oxidase inhibitors. Proc Soc Exp Biol Med. 1996;211:366-373.
49. De Tombe PP, Jones S, Burkhoff D, Hunter WC, Kass DA. Ventricular stroke work and efficiency both remain nearly optimal despite altered vascular loading. Am J Physiol. 1993;264:H1817-H1824.
50. Rusy BF, Komai H. Anesthetic depression of myocardia, contractility: a review of possible mechanisms. Anesthesiology. 1987;67:745-766.
51. Merin RG. Inhalation anesthetics and myocardial metabolism: possible mechanisms of functional effects. Anesthesiology. 1973;39:216-255.